Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry
April 24, 2015
- Council on Unapproved Drugs to Issue Development Requests Immediately In Cases of Unanimous Approval by Working Groups
April 24, 2015
- MHLW Orders Revision of Package Inserts for Plavix
April 24, 2015
- Polyethylene Glycol Has Great Unmet Medical Need: Panel
April 23, 2015
- MHLW Official Jo Hints at Possible Move-Up of Generic Roadmap
April 23, 2015
- Find Solid Candidates from Early Development Stage: MHLW’s Mori
April 23, 2015
- Ease Post-Marketing Burdens for Intractable Disease Treatments: JPMA Exec
April 22, 2015
- AMED Chief Envisages Tapping Private Funds to Fuel R&D
April 22, 2015
- Editor’s Pick: Five Healthcare News Headlines for April 6 - 19
April 20, 2015
- Govt Checks on Progress of Healthcare R&D Promotion Plan
April 20, 2015
- Govt Panel Members Call for Medication Control to Eliminate Unused Drugs
April 17, 2015
- Govt Panel to Prod Chuikyo to Revisit 14-Day Prescription Limit
April 17, 2015
- Who Will Foot the Bill for Cost-Effective Assessments?: Chuikyo Chair
April 16, 2015
- Japan Faces Imperative to Increase Biostatisticians to Boost Clinical Research Quality
April 16, 2015
- PAFSC 1st Committee to Discuss Add’l Indication for Cymbalta on April 28
April 15, 2015
- “Proper Management” Essential in Company Funding of Academic Research: MHLW Official
April 15, 2015
- PMDA Invites People with Broad Perspective from the Medical Community to Join PMDA: Chief Executive
April 15, 2015
- MHLW Official Introduces Patient ADR Reporting System
April 15, 2015
- Cost-Effectiveness Case Study to Be Reported to Chuikyo in May: Official
April 14, 2015
- If Cost-Effective Assessment Is Used to Set Drug Prices, Focus Will Be on Impact on Pricing Rules: Ex-Chuikyo Member
April 14, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…